AbbreviAtions AACe = American Association of Clinical
Endocrinologists; ACs = American College of Surgery; AsMbs = American Association of Metabolic and Bariatric Surgery; bAC = blood alcohol content; beD = binge eating disorder; beL = best evidence level; bMi = body mass index; bPD-Ds = biliopancreatic diversion with duodenal switch; CCs = clinical case series; CK = creatine kinase; CPAP = continuous positive airway pressure; CPG = clinical practice guidelines; Css = cross-sectional study; Ct = computerized tomography; CvD = cardiovascular disease; DCCP = diabetes comprehensive care plan; Dvt = deep venous thrombosis; DXA = dual-energy x-ray absorptiometry; eL = evidence level; en = enteral nutrition; FDA = U.S. Food and Drug Administration; GerD = gastrointestinal reflux disease; HDL = high-density lipoprotein; iCU = intensive care unit; LAbs = longitudinal assessment of bariatric surgery; LAGb = laparoscopic adjustable gastric band; LDL = low-density lipoprotein; LsG = laparoscopic sleeve gastrectomy; Mi = myocardial infarction; MnrCt = meta-analysis of nonrandomized controlled trials; MrCt = meta-analysis of randomized controlled trials; nAFLD = nonalcoholic fatty liver disease; nAsH = nonalcoholic steatohepatitis; ne = no evidence; niH = National Institutes of Health; oHs = obesity hypoventilation syndrome; osA = obstructive sleep apnea; os-Mrs = obesity surgery mortality risk score; PtH = parathyroid hormone; PCos = polycystic ovary syndrome; PCs = prospective cohort study; Pe = pulmonary embolism; Pn = parenteral nutrition; PPi = proton pump inhibitor; rCt = randomized controlled trial; rML = rhabdomyolysis; rYGb = Roux-en-Y gastric bypass; sCr = single case report; sG = sleeve gastrectomy; sos = Swedish Obesity Subjects; ss = surveillance survey; t2D = type 2 diabetes mellitus; tos = The Obesity Society; tsH = thyroid-stimulating hormone; UGi = upper gastrointestinal; vte = venous thromboembolism.
AbstrACt
The development of these updated guidelines was commissioned by the AACE, TOS, and ASMBS Board of Directors and adheres to the AACE 2010 protocol for standardized production of clinical practice guidelines (CPG). Each recommendation was re-evaluated and updated based on the evidence and subjective factors per protocol. Examples of expanded topics in this update include: the roles of sleeve gastrectomy, bariatric surgery in patients with type-2 diabetes, bariatric surgery for patients with mild obesity, copper deficiency, informed consent, and behavioral issues. There are 74 evidence base (Q1-7) references introDUCtion Obesity continues to be a major public health problem in the United States, with more than one-third of adults considered obese in 2009-2010, as defined by a body mass index (BMI) ≥30 kg/m 2 (1 [EL 3, SS]). Obesity has been associated with an increased hazard ratio for all-cause mortality (2 [EL 3, SS]), as well as significant medical and psychological co-morbidity. Indeed, obesity is not only a chronic medical condition but should be regarded as a bona fide disease state (3 [EL 4, NE] ). Nonsurgical management can effectively induce 5%-10% weight loss and improve health in severely obese individuals (4 [EL 1, RCT]) resulting in cardiometabolic benefit. Bariatric surgery procedures are indicated for patients with clinically severe obesity. Currently, these procedures are the most successful and durable treatment for obesity. Furthermore, although overall obesity rates and bariatric surgery procedures have plateaued in the United States, rates of severe obesity are still increasing and now there are approximately 15 million people in the United States with a BMI ≥40 kg/m 2 (1 [EL 3, SS]; 5 [EL 3, SS]). Only 1% of the clinically eligible population receives surgical treatment for obesity (6 [EL 3, SS] ). Given the potentially increased need for bariatric surgery as a treatment for obesity, it is apparent that clinical practice guidelines (CPG) on the subject keep pace and are kept current.
Since the 2008 TOS/ASMBS/AACE CPG for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient (7 [EL 4 ; CPG]), significant data have emerged regarding a broader range of available surgeries for the treatment of obesity. A PubMed computerized literature search (performed on December 15, 2012) using the search term "bariatric surgery" reveals a total of 14,287 publications with approximately 6,800 citations from 2008 to 2012. Updated CPG are therefore needed to guide clinicians in the care of the bariatric surgery patient. What are the salient advances in bariatric surgery since 2008? The sleeve gastrectomy (SG; laparoscopic SG [LSG] ) has demonstrated benefits comparable to other bariatric procedures and is no longer considered investigational (8 [EL 4, NE]). A national risk-adjusted database positions SG between the laparoscopic adjustable gastric band (LAGB) and laparoscopic Roux-en-Y gastric bypass (RYGB) in terms of weight loss, co-morbidity resolution, and complications (9 [EL 2, PCS]). The number of SG procedures has increased with greater third-party pay or coverage (9 [EL 2, PCS]). Other unique procedures are gaining attention, such as gastric plication, electrical neuromodulation, and endoscopic sleeves, but these procedures lack sufficient outcome evidence and therefore remain investigational and outside the scope of this CPG update.
There is also emerging data on bariatric surgery in specific patient populations, including those with mild to moderate obesity, type 2 diabetes (T2D) with class I obesity (BMI 30-34.9 kg/m 2 ), and patients at the extremes of age. Clinical studies have demonstrated short-term efficacy of LAGB in mild to moderate obesity (10 2 with T2D or other obesity-related co-morbidities (14 [EL 4, NE] ). Although controversial, this position was incorporated by the International Diabetes Federation, which proposed eligibility for bariatric procedures in a subset of patients with T2D and a BMI of 30 kg/m 2 with suboptimal glycemic control despite optimal medical management (15 [EL 4, NE] ). Thus, the term metabolic surgery has emerged to describe procedures intended to treat T2D as well as reduce cardiometabolic risk factors. In 1 study, metabolic surgery was shown to induce T2D remission in up to 72% of subjects at 2 years; however, this number was reduced to 36% at 10 years (16 [EL 2, PCS]). In a more recent study, patients who underwent RYGB sustained diabetes remission rates of 62% at 6 years (17 [EL 2, PCS]). The overall long-term effect of bariatric surgery on T2D remission rates is currently not well studied. Additionally, for patients who have T2D recurrence several years after surgery, the legacy effects of a remission period on their long-term cardiovascular risk is not known. The mechanism of T2D remission has not been completely elucidated but appears to include an incretin effect (SG and RYGB procedures) in addition to caloric restriction and weight loss. These findings potentially expand the eligible population for bariatric and metabolic surgery.
Another area of recent interest is the use of bariatric surgery at the extremes of age. Historically, the 1991 National Institutes of Health (NIH) consensus criteria stipulated that treatment of obesity with bariatric surgery is limited to adults (18 [EL 4, NE] ). Until 2003, <.7% of bariatric procedures were performed in adolescents (age <20 years) ( Advanced age >45 years has also been cited as a risk factor for bariatric surgery in some series; however, the data have been conflicting. Prospective data collected from a single academic center demonstrated that patients age ≥55 years had a 3-fold mortality compared with younger patients (21 [EL 3, SS] ). However, recent American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) data of 48,378 patients failed to reveal advanced age to be associated with statistically significant mortality compared with controls (22 [EL 3, SS] ). Although many bariatric programs have established arbitrary cutoff levels for age at 65-70 years, other programs primarily consider overall health risks and physiological status.
The Obesity Surgery Mortality Risk Score (OS-MRS) by DeMaria et al. (23, 24 ) identified 5 preoperative risk factors that predicted increased risk of 30-day morbidity and mortality after RYGB. These included advanced age (≥45 years), "super-obesity" (BMI ≥50 kg/m 2 ), hypertension, male gender, and pulmonary embolism (PE) In another cohort, all-cause mortality was reduced by 40% 7 years after RYGB, compared with the control group, and cause-specific mortality in the surgery group decreased by 56% for coronary artery disease, by 92% for T2D, and by 60% for cancer (27 [EL 2, RCCS]).
As the prevalence of obesity has grown in the United States, so too has the number of bariatric operations for the surgical treatment of obesity. Promising pharmacological (including biological) treatments are on the horizon, but at present, bariatric surgery remains superior to nonsurgical treatments in terms of short-term benefits in surrogate markers of metabolic disease. Durability of benefit in terms of pertinent clinical outcomes will be the endpoints of current prospective trials. An enriched evidence base, expanding eligible patient populations, and safer, innovative surgical treatments for obesity will likely result in a greater number of obese patients undergoing surgery.
This CPG update aims to keep pace with the evidencebased literature, and along with the accompanying checklist (28 [EL 4]), assist physicians and allied health professionals with both routine and difficult clinical decision making. Tables 1-4 . This updated CPG methodology has the advantage of greater transparency, diligence, and detail for mapping the strength of evidence and expert opinion into a final graded recommendation. Nevertheless, as with all white papers, there is an element of subjectivity that must be recognized by the reader when interpreting the information. The Executive Summary is reorganized by clinical questions and provides updated recommendation numbers (R1, R2, R3, … R100) with original recommendation numbers in parentheses, and an appended "-r," indicating substantive content or grading revision, or "-NEW," indicating new content. In many cases, recommendations have been condensed for clarity and brevity. In other cases, recommendations have been expanded for more clarity for complex decision making. 
Methods

Q1. Which patients should be offered bariatric surgery?
r1(1)-r. Patients with a BMI ≥40 kg/m 2 without coexisting medical problems and for whom bariatric surgery would not be associated with excessive risk should be eligible for 1 of the procedures (Grade A; beL 1). r2(2/3)-r. Patients with a BMI ≥35 kg/m 2 and 1 or more severe obesity-related co-morbidities, including T2D, hypertension, hyperlipidemia, obstructive sleep apnea (OSA), obesity-hypoventilation syndrome (OHS), Pickwickian syndrome (a combination of OSA and OHS), nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), pseudotumor cerebri, gastroesophageal reflux disease (GERD), asthma, venous stasis disease, severe urinary incontinence, debilitating arthritis, or considerably impaired quality of life, may also be offered a bariatric procedure. Patients with BMI of 30-34.9 kg/m 2 with diabetes or metabolic syndrome may also be offered a bariatric procedure, although current evidence is limited by the number of subjects studied and lack of longterm data demonstrating net benefit.
• 
r3(4)-r.
There is insufficient evidence for recommending a bariatric surgical procedure specifically for glycemic control alone, lipid lowering alone, or cardiovascular disease risk reduction alone, independent of BMI criteria (Grade D).
Q2. Which bariatric surgical procedure should be offered?
r4(5/6/7)-r. The best choice for any bariatric procedure (type of procedure and type of approach) depends on the individualized goals of therapy (e.g., weight loss and/ or metabolic [glycemic] control), available local-regional expertise (surgeon and institution), patient preferences, and personalized risk stratification (Grade D). At this time, there is still insufficient evidence to generalize in favor of one bariatric surgical procedure for the severely obese population (Grade D). In general, laparoscopic bariatric procedures are preferred over open bariatric procedures due to lower early postoperative morbidity and mortality (Grade b; beL 2). Laparoscopic adjustable gastric banding (LAGB), laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (RYGB), and laparoscopic biliopancreatic diversion BPD, BPD/duodenal switch (BPD-DS), or related procedures are primary bariatric and metabolic procedures that may be performed in patients requiring weight loss and/or metabolic control (Grade A; beL 1). Physicians should exercise caution when recommending BPD, BPD-DS, or related procedures because of the greater associated nutritional risks related to the increased length of bypassed small intestine (Grade A; beL 1). Investigational procedures may be considered for selected patients based on available institutional review board (IRB) approved protocols, suitability for clinical targets and individual patient factors, and only after a careful assessment balancing the importance for innovation, patient safety, and demonstrated effectiveness (Grade D).
Q3. How should potential candidates for bariatric surgery be managed preoperatively?
r5(8). All patients should undergo preoperative evaluation for obesity-related co-morbidities and causes of obesity, with special attention directed to those factors that could affect a recommendation for bariatric surgery (see Preoperative Checklist in Table 5 ) (Grade A; beL 1). r6 (9) . The preoperative evaluation must include a comprehensive medical history, psychosocial history, physical examination (see Table 16 in ref [6] ), and appropriate laboratory testing to assess surgical risk (Table 6 ) (Grade A; beL 1). r7(10). The medical necessity for bariatric surgery should be documented (Grade D). r8(11/12)-r. Because informed consent is a dynamic process, there should be a thorough discussion with the patient regarding the risks and benefits, procedural options, choices of surgeon and medical institution, and the need for long-term follow-up and vitamin supplementation (including costs required to maintain appropriate followup) (Grade D). Patients should also be provided with educational materials and access to preoperative educational sessions at prospective bariatric surgery centers (Grade D). Consent should include experience of the surgeon with the specific procedure offered and whether the hospital has an accredited bariatric surgery program (Grade D). r19(32/33)-r. In patients considered for bariatric surgery, chest radiograph and standardized screening for obstructive sleep apnea (with confirmatory polysomnography if screening tests are positive) should be considered. (Grade C, beL 3). Patients with intrinsic lung disease or disordered sleep patterns should have a formal pulmonary evaluation, including arterial blood gas measurement, when knowledge of the results would alter patient care (Grade C; beL 3). r20(34/157)-r. Tobacco use should be avoided at all times by all patients. In particular, patients who smoke cigarettes should stop, preferably at least 6 weeks before bariatric surgery (Grade A; beL 2, upgraded by consensus). Also, tobacco use should be avoided after bariatric surgery given the increased risk for of poor wound healing, anastomotic ulcer, and overall impaired health (Grade A; beL 1).
r21(35/36)-r. Patients with a history of deep venous thrombosis (DVT) or cor pulmonale should undergo an appropriate diagnostic evaluation for DVT (Grade D). A prophylactic vena caval filter may present a greater risk than benefit in patients with a history of prior PE or DVT given the risks of filter-related complications including thrombosis (Grade C; beL 3). r22(37). Clinically significant gastrointestinal symptoms should be evaluated before bariatric surgery with imaging studies, upper gastrointestinal (UGI) series, or endoscopy (Grade D).
r23(38)-r. Abdominal ultrasound is not recommended as a routine screen for liver disease (Grade C, beL 3). Abdominal ultrasound is indicated to evaluate symptomatic biliary disease and elevated liver function tests. In patients with increased liver function tests (2 to 3 times the upper limit of normal), abdominal ultrasonography and a viral hepatitis screen may be considered (Grade D). Consideration can be made for liver biopsy at the time of surgery to document steatohepatitis and/or cirrhosis that may otherwise be unknown due to normal appearance and/ or liver function tests (Grade D).
r24(39)-r. Routine screening for the presence of Helicobacter pylori before bariatric surgery may be considered in high-prevalence areas (Grade C; beL 3).
r25(40)-r. Before bariatric surgery, prophylactic treatment for gouty attacks should be considered in patients with a history of gout (Grade C, beL 3). r26(41). There are insufficient data to warrant preoperative assessment of bone mineral density with dualenergy x-ray absorptiometry (DXA) outside formal CPG recommendations by the National Osteoporosis Foundation (www.nof.org) (Grade D). r27(42/43)-r. A psychosocial-behavioral evaluation, which assesses environmental, familial, and behavioral factors, should be required for all patients before bariatric surgery (Grade C; beL 3). Any patient considered for bariatric surgery with a known or suspected psychiatric illness, or substance abuse, or dependence, should undergo a formal mental health evaluation before performance of the surgical procedure (Grade C; beL 3). Following RYGB, high-risk groups should eliminate alcohol consumption due to impaired alcohol metabolism and risk of alcohol use disorder postoperatively (Grade C; beL 3).
r28(44)-r. All patients should undergo evaluation of their ability to incorporate nutritional and behavioral changes before and after bariatric surgery (Grade C; beL 3). r29(45)-r. All patients should undergo an appropriate nutritional evaluation, including micronutrient measurements, before any bariatric surgical procedure. In comparison with purely restrictive procedures, more extensive perioperative nutritional evaluations are required for malabsorptive procedures (Grade A; beL 1).
r30(NEW). Patients should be followed by their primary care physician and have age and risk appropriate cancer screening before surgery. Grade C; beL 3). Protein intake should be individualized, assessed, and guided by an RD, in reference to gender, age, and weight (Grade D). A minimal protein intake of 60 g/d and up to 1.5 g/kg ideal body weight per day should be adequate; higher amounts of protein intake-up to 2.1 g/kg ideal body weight per day-need to be assessed on an individualized basis (Grade D). Concentrated sweets should be eliminated from the diet after RYGB to minimize symptoms of the dumping syndrome, as well as after any bariatric procedure to reduce caloric intake (Grade D). Crushed or liquid rapid-release medications should be used instead of extended-release medications to maximize absorption in the immediate postoperative period (Grade D).
r32(54/89/93)-r. After consideration of risks and benefits, patients with, or at risk for, demonstrable micronutrient insufficiencies or deficiencies should be treated with the respective micronutrient (Grade A, beL 2, upgraded by consensus). Minimal daily nutritional supplementation for patients with RYGB and LSG all in chewable form initially (i.e., 3 to 6 months), should include 2 adult multivitamin plus mineral (each containing iron, folic acid, and thiamine) supplements (Grade b, beL 2), 1200 to 1500 mg of elemental calcium (in diet and as citrated supplement in divided doses) (Grade b, beL 2), at least 3000 international units of vitamin D (titrated to therapeutic 25-hydroxyvitamin D levels >30 ng/ml) (Grade A, beL 1), and vitamin B 12 (parenterally as sublingual, subcutaneous, or intramuscular preparations, or orally, if determined to be adequately absorbed) as needed to maintain B12 levels in the normal range (Grade b; beL 2). Total iron provided should be 45-60 mg via multivitamins and additional supplements. Minimal daily nutritional supplementation for patients with LAGB should include 1 adult multivitamin plus mineral (including iron, folic acid, and thiamine) (Grade b, beL 2), 1200 to 1500 mg of elemental calcium (in diet and as citrated supplement in divided doses) (Grade b, beL 2), at least 3000 international units of vitamin D (titrated to therapeutic 25-dihydroxyvitamin D levels). Alternatively, in lieu of routine screening with relatively costly biochemical testing, the above routine micronutrient supplementation may be initiated preoperatively (Grade D).
r33(55)-r. Fluids should be consumed slowly, preferably at least 30 minutes after meals to prevent gastrointestinal symptoms, and in sufficient amounts to maintain adequate hydration (more than 1. r35(57)-r. In patients with T2D, periodic fasting blood glucose concentrations should be determined (Grade A; beL 1). Preprandial, 2-hour postprandial, and bedtime reflectance meter glucose (RMG; "fingerstick") determinations in the home setting should also be encouraged, depending on the patient's ability to test, the level of glycemic control targeted, use of oral agents or insulin, and overall care plan (Grade A; beL 1). RMG determinations should also be performed if symptoms of hypoglycemia occur (Grade A; beL 1).
r36(58-61)-r. In patients with diabetes, the use of all insulin secretagogues (sulfonylureas and meglitinides) should be discontinued and insulin doses should be adjusted postoperatively (due to low calorie intake) to minimize the risk for hypoglycemia (Grade D). Antidiabetic medications should be withheld if the T2D is in remission following bariatric surgery (Grade D). Metformin may be continued postoperatively until prolonged clinical resolution of diabetes is demonstrated by normalized glycemic targets (including fasting and postprandial blood glucose and HbA 1c ). Insulin therapy, using a rapid-acting insulin analogue (insulin lispro, aspart, or glulisine) before meals and a basal long-acting insulin analogue (insulin glargine or detemir) should be used to attain glycemic targets (140-180 mg/dL) in nonintensive care unit hospitalized patients (Grade D). In the intensive care unit, intravenous regular insulin, as part of a standard intensive insulin therapy protocol, should be used to control hyperglycemia to a 140-180 mg/dL blood glucose target (Grade D). Antidiabetic medications that improve insulin sensitivity (metformin), as well as incretin-based therapies, should be considered in outpatients not reaching glycemic targets. (Grade D). Endocrinology consultation should be considered for patients with uncontrolled hyperglycemia (Grade D). r37(62)-r. Patients with high perioperative risk for myocardial infarction should be managed in a monitored telemetry setting for at least the first 24 hours postoperatively (Grade D). r38(64)-r. Pulmonary management includes aggressive pulmonary toilet and incentive spirometry, oxygen supplementation to avoid hypoxemia, and early institution of continuous positive airway pressure (CPAP) when clinically indicated (Grade C, beL 3). r39(65/66)-r. Prophylaxis against deep venous thrombosis (DVT) is recommended for all patients (Grade b; beL 2). Prophylactic regimens after bariatric surgery include sequential compression devices (Grade C; beL 3), as well as subcutaneously administered unfractionated heparin or low-molecular-weight heparin given within 24 hours after bariatric surgery (Grade b; beL 2). Extended chemoprophylaxis after hospital discharge should be considered for high-risk patients, such as those with history of DVT (Grade C, beL 3). Early ambulation is encouraged (Grade C; beL 3). r40(67-71)-r. Respiratory distress or failure to wean from ventilatory support should raise suspicion and prompt an evaluation for an acute postoperative complication, such as pulmonary embolus (PE) or anastomotic leak (Grade D). In the clinically stable patient, UGI studies (water-soluble contrast followed by thin barium) or computed tomography (CT) may be considered to evaluate for anastomotic leaks in suspected patients (Grade C; beL 3). Exploratory laparotomy or laparoscopy is justified in the setting of high clinical suspicion for anastomotic leaks despite a negative study (Grade C; beL 3). The presence of a new sustained pulse rate of more than 120 beats/ min for longer than 4 hours, tachypnea, hypoxia, or fever, should raise concern for an anastomotic leak (Grade D). A selected Gastrografin upper gastrointestinal (UGI) study in the absence of abnormal signs or symptoms may be considered to identify any subclinical leaks before discharge of the patient from the hospital, although routine studies are not cost effective. (Grade C; beL 3). C-reactive protein (CRP) testing should be considered if a postoperative leak is suspected. r41(72-75)-r. Patients should have adequate padding at pressure points during bariatric surgery (Grade D). When rhabdomyolysis (RML) is suspected, creatine kinase (CK) levels should be determined, urine output monitored, and adequate hydration ensured (Grade C; beL 3). The risk for RML increases as BMI increases (particular with BMI >55-60 kg/m 2 ); therefore, screening CK levels may be tested in these higher risk groups (Grade D).
Q6. How can optimal follow-up of bariatric surgery be achieved?
r42(78-83/85/88)-r. The frequency of follow up depends on the bariatric procedure performed and the severity of co-morbidities (Grade D). Following LAGB, frequent nutritional follow-up and/or band adjustments are important for maximal weight loss (Grade C; beL 3). Significant weight regain or failure to lose weight should prompt evaluation for (a) decreased patient adherence with lifestyle modification, (b) evaluation of medications associated with weight gain or impairment of weight loss, (c) development of maladaptive eating behaviors, (d) psychological complications, and (e) radiographic or endoscopic evaluation to assess pouch enlargement, anastomotic dilation, formation of a gastrogastric fistula among patients who underwent a RYGB, or inadequate band restriction among patients who underwent a LAGB (Grade b; beL 2). Interventions should first include a multidisciplinary approach, including dietary change, physical activity, behavioral modification with frequent follow up; and then if appropriate, pharmacologic therapy and/or surgical revision (Grade b; beL 2). In those patients with or without complete resolution of their T2D, dyslipidemia, or hypertension, continued surveillance and management should be guided by current clinical practice guidelines for those conditions (Grade D). Routine metabolic and nutritional monitoring is recommended after all bariatric surgical procedures (Grade A; beL 1). r43(84)-r. Patients who have undergone RYGB, BPD, or BPD/DS and who present with postprandial hypoglycemic symptoms that have not responded to nutritional manipulation should undergo an evaluation to differentiate noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) from factitious or iatrogenic causes, dumping syndrome, and insulinoma (Grade C; beL 3). In patients with NIPHS, therapeutic strategies include dietary changes (low carbohydrate diet), octreotide, diazoxide, acarbose, calcium channel antagonists, gastric restriction, and reversal procedures, with partial or total pancreatectomy reserved for the rare recalcitrant cases (Grade C; beL 3).
r44 (86) 12 deficiency is recommended in all bariatric surgery and annually in those with procedures that exclude the lower part of the stomach (e.g., LSG, RYGB) (Grade b; beL 2). Oral supplementation with crystalline vitamin B 12 at a dosage of 1000 μg daily or more may be used to maintain normal vitamin B 12 levels (Grade A; beL 1). Intranasally administered vitamin B 12 , 500 μg weekly, may also be considered (Grade D). Parenteral (intramuscular or subcutaneous) B 12 supplementation, 1000 μg/mo to 1000-3000 μg every 6 to 12 months, is indicated if B 12 sufficiency cannot be maintained using oral or intranasal routes (Grade C; beL 3).
r55(117)-r. Folic acid supplementation (400 μg/d) should be part of a routine mineral-containing multivitamin preparation (Grade b; beL 2) and should be supplemented in all women of childbearing age to reduce the risk of fetal neural tube defects (Grade A; beL 1). r56(119)-r. Nutritional anemias resulting from malabsorptive bariatric surgical procedures might also involve deficiencies in vitamin B 12 , folate, protein, copper, selenium, and zinc and should be evaluated when routine screening for iron deficiency anemia is negative (Grade C; beL 3). r57(120/121)-r. There is insufficient evidence to support routine selenium screening or supplementation after bariatric surgery (Grade D). However, selenium levels should be checked in patients with a malabsorptive bariatric surgical procedure who have unexplained anemia or fatigue, persistent diarrhea, cardiomyopathy, or metabolic bone disease (Grade C; beL 3). r58(122/123)-r. Routine screening for zinc deficiency should occur after malabsorptive bariatric surgical procedures (Grade C; beL 3) and should be routinely supplemented following BPD/BPDDS (Grade C; beL 3). Zinc deficiency should be considered in patients with hair loss, pica, significant dysgeusia, or in male patients with hypogonadism or erectile dysfunction (Grade D). r65(139-141)-r. Endoscopy may be the preferred procedure for gastrointestinal symptoms suggestive of stricture or foreign body (e.g., suture, staple) as it can be both diagnostic and therapeutic (endoscopic dilation or foreign body removal) (Grade C; beL 3). Evaluation can also include H pylori testing as a possible contributor to persistent gastrointestinal symptoms after bariatric surgery (Grade D). Anastomotic ulcers should be treated with H 2 receptor blockers, proton pump inhibitors (PPI), sucralfate, and if H pylori is identified, triple therapy to include antibiotics, bismuth, and PPI (Grade C; beL 3). r66(142)-r. Patients who previously underwent a RYGB with a nonpartitioned stomach who develop a gastrogastric fistula or herniation with symptoms of weight regain, marginal ulcer, stricture or gastroesophageal reflux, may benefit from a revisional procedure (Grade C; beL 3). r67(143/144). Persistent vomiting, regurgitation, and UGI obstruction after LAGB should be treated with immediate removal of fluid from the adjustable band (Grade D). Persistent symptoms of gastroesophageal reflux, regurgitation, chronic cough, or recurrent aspiration pneumonia after LAGB raise concern for the band being too tight or the development of an abnormally large gastric pouch above the band or esophageal dilation. These symptoms should prompt immediate referral to a bariatric surgeon (Grade D).
r68(145/146)-r. Ultrasound should be used to evaluate patients with right upper quadrant pain for cholecystitis (Grade D). Prophylactic cholecystectomy may be considered with RYGB to prevent gallbladder complications (Grade b; beL 2). Oral administration of ursodeoxycholic acid, at least 300 mg daily in divided doses, significantly decreases gallstone formation after RYGB and may be considered for use in patients after bariatric surgery who have not had a cholecystectomy (Grade A; beL 1). r69(147/148)-r. Although uncommon, suspected bacterial overgrowth in the biliopancreatic limb after BPD or BPD/DS should be treated empirically with metronidazole or rifaximin (Grade C; beL 3). For antibiotic-resistant cases of bacterial overgrowth, probiotic therapy with Lactobacillus plantarum 299v and Lactobacillus GG may be considered (Grade D). r70(149-152). Definitive repair of asymptomatic abdominal wall hernias can be deferred until weight loss has stabilized and nutritional status has improved, to allow for adequate healing (12 to 18 months after bariatric surgery) (Grade D). Symptomatic hernias that occur after bariatric surgery require prompt surgical evaluation (Grade C; beL 3). Patients with sudden onset, severe cramping periumbilical pain or recurrent episodes of severe abdominal pain anytime after weight loss surgery should be evaluated with an abdominal and pelvic CT scan to exclude the potentially life-threatening complication of a closed loop bowel obstruction (Grade D). Exploratory laparotomy or laparoscopy is indicated in patients who are suspected of having an internal hernia because this complication can be missed with upper gastrointestinal (UGI) x-ray studies and CT scans (Grade C; beL 3). r71(153-156)-r. Body-contouring surgery may be performed after bariatric surgery to manage excess tissue that impairs hygiene, causes discomfort, and is disfiguring (Grade C; beL 3). This surgery is best pursued after weight loss has stabilized (12 to 18 months after bariatric surgery) (Grade D). 
Q7. What
Q1. Which patients should be offered bariatric surgery?
r1(1).The evidence base for recommending bariatric surgery for patients with BMI ≥40 kg/m 2 without coexisting medical problems is enriched with recent EL 1-3 studies demonstrating benefit: mortality ( 2 and does not apply to this CPG recommendation. Future, well-designed clinical trials that incorporate longer follow-up periods with demonstration of safety in the surgical group, relevant CVD outcomes, and an intensive medical therapy comparator group associated with weight loss, will clarify this CPG recommendation for patients with BMI <35 kg/m 2 .
r3(4). There are no compelling studies to date that support recommending a bariatric surgical procedure for the management of T2D alone, in the absence of obesity (BMI <30 kg/m 2 ).
Q2. Which bariatric surgical procedure should be offered?
r4(5/6/7). Two principal determinants since publication of the 2008 AACE-TOS-ASMBS CPG (7 [EL 4;
CPG]) have impacted clinical decision making regarding the choice of a specific bariatric surgery procedure (see Fig. 1 for depictions of the 4 common bariatric surgery procedures). First, the emphasis has shifted from weight-loss outcomes to the metabolic effects of bariatric surgery procedures, and second, sufficient data regarding the safety, efficacy, and durability of various procedures, especially the LSG, have been published. The advent of personalized medicine and applicability to obesity genetics and medicine is reviewed by Blakemore As the metabolic effects of various bariatric operations become better understood, the traditional classifications of procedures as "restrictive," "malabsorptive," or "combination" procedures have become less functional and less widely accepted. Adjustable gastric banding has clearly been shown to result in improvement or remission of diabetes and metabolic syndrome (50 [EL 2, RCT]), but it appears that these effects may not be related to changes in gut hormones (67 [EL 2, PCS]). The early, weightindependent effects of RYGB, BPD/BPDDS, and LSG on T2D improvement have led many to refer to these procedures as "metabolic" operations ( The LSG has become widely accepted as a primary bariatric operation and is no longer considered investigational (see ASMBS statement at http://s3.amazonaws.com/ publicASMBS/GuidelinesStatements/PositionStatement/ ASMBS-SLEEVE-STATEMENT-2011_10_28.pdf [accessed on May 22, 2012] ). The LSG is seldom used as part of a 2-stage risk management strategy for highrisk patients. Because nearly 80% of the stomach is transected and nutrients rapidly pass through a gastric conduit, increased GLP-1 and PYY 3-36 and decreased ghrelin levels result, producing key metabolic effects (78 3, SS] ). In another retrospective review of 560 patients undergoing RYGB, flexible upper endoscopy, testing for H pylori followed by treatment of patients with positive results, was associated with a lower incidence of postoperative marginal ulcers (2.4%), compared with those who did not undergo such screening (6.8%) (197 A lifetime history of substance abuse disorder is more likely in bariatric surgery candidates compared with the general population (211 [EL 3, SS]). In contrast, current alcohol and substance abuse in bariatric surgery candidates is low compared with the general population (211  [EL 3, SS] ). The LABS study demonstrated that certain groups including those with regular preoperative alcohol consumption, alcohol use disorder, recreational drug use, smokers, and those undergoing RYGB had a higher risk of postoperative alcohol use disorder (212 [EL 2, PCS]). A web-based questionnaire study indicated that 83% of respondents continued to consume alcohol after RYGB, with 28.4% indicating a problem controlling alcohol (213 [EL 3, SS]). In a prospective study with 13-to 15-year follow-up after RYGB, there was an increase in alcohol abuse (2.6% presurgery to 5.1% postsurgery) but a decrease in alcohol dependence (10.3% presurgery versus 2.6% postsurgery) (214 [EL 2, PCS]). In a survey 6-10 years after RYGB, 7.1% of patients had alcohol abuse or dependence before surgery, which was unchanged postoperatively, whereas 2.9% admitted to alcohol dependence after surgery but not before surgery ( found that among 1,566 undergoing bariatric surgery, 36 (2.3%) had a history of malignancy, 4 (.3%) were diagnosed during the preoperative evaluation, 2 (.1%) were diagnosed intraoperatively, and another 16 (1%) were diagnosed postoperatively. However, the authors commented that a finding of malignancy per se was not a contraindication to bariatric surgery as long as the life expectancy was reasonable. Subsequently, limited clinical series have described the benefit of preoperative screening 3 , CSS]) found that bone mineral density (BMD) was positively correlated with lean mass preoperatively and postoperatively and with fat mass preoperatively. However, the authors point out that causal mechanisms among body composition, BMD, and neurohumoral axes remain complex and require further study. Even with the bone loss in the hip after bariatric surgery, the data and limitations of dual energy x-ray absorptiometry (DXA) are not conclusive that there is an increased incidence of osteoporosis and increased fracture risk (354 [EL 4, review] found that among RYGB patients developing thiamine deficiency, they also had evidence of small intestine bacterial overgrowth (SIBO), which responded to thiamine 100 mg PO BID for 2 months (on average) and antibiotics (metronidazole, amoxicillin, or rifaximin for 7-10 days each month for 2 months on average). The authors concluded that SIBO impairs the absorption of thiamine, as well as other nutrients.
r61 (130) . Improvements in serum lipid levels after bariatric surgery have been well documented and are multifactorial in nature (GI absorption, altered dietary patterns, and not weight loss per se). The continued need for lipid-lowering medication, especially statins, unless overtly unnecessary or not possible due to GI symptoms, is emphasized, though the evidence base is fairly limited (364 [EL 3, SS] 
